143 related articles for article (PubMed ID: 32106724)
1. Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739.
Millán-Pérez Peña L; Martin PS; Herrera-Camacho I; Bandala C; Anaya-Ruiz M
Expert Opin Ther Pat; 2020 May; 30(5):307-311. PubMed ID: 32106724
[No Abstract] [Full Text] [Related]
2. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L; Rosas-Murrieta NH
Expert Opin Ther Pat; 2019 Dec; 29(12):921-924. PubMed ID: 31627712
[No Abstract] [Full Text] [Related]
3. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.
Herrera-Camacho I; Anaya-Ruiz M; Perez-Santos M; Millán-Pérez Peña L; Bandala C; Landeta G
Expert Opin Ther Pat; 2019 Aug; 29(8):587-593. PubMed ID: 31241380
[No Abstract] [Full Text] [Related]
4. Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054.
Cebada J; Flores A; Bandala C; Lizaliturri-Flores I; Villa-Ruano N; Perez-Santos M
Expert Opin Ther Pat; 2020 Jul; 30(7):487-494. PubMed ID: 32397849
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652.
Perez-Santos M; Guerrero-González T; Gómez-Conde E; Cebada J; Flores A; Villa-Ruano N
Expert Opin Ther Pat; 2020 Mar; 30(3):159-162. PubMed ID: 31944149
[No Abstract] [Full Text] [Related]
6. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy.
Riccardi C; Ronchetti S; Nocentini G
Expert Opin Ther Targets; 2018 Sep; 22(9):783-797. PubMed ID: 30107134
[TBL] [Abstract][Full Text] [Related]
8. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
9. An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.
Chan S; Belmar N; Ho S; Rogers B; Stickler M; Graham M; Lee E; Tran N; Zhang D; Gupta P; Sho M; MacDonough T; Woolley A; Kim H; Zhang H; Liu W; Zheng P; Dezso Z; Halliwill K; Ceccarelli M; Rhodes S; Thakur A; Forsyth CM; Xiong M; Tan SS; Iyer R; Lake M; Digiammarino E; Zhou L; Bigelow L; Longenecker K; Judge RA; Liu C; Trumble M; Remis JP; Fox M; Cairns B; Akamatsu Y; Hollenbaugh D; Harding F; Alvarez HM
Nat Cancer; 2022 Mar; 3(3):337-354. PubMed ID: 35256819
[TBL] [Abstract][Full Text] [Related]
10. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
[No Abstract] [Full Text] [Related]
11. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
12. Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232.
Villa-Ruano N; Guerrero-González T; Gómez-Conde E; Perez-Santos M
Expert Opin Ther Pat; 2020 Oct; 30(10):723-727. PubMed ID: 32787475
[TBL] [Abstract][Full Text] [Related]
13. Rationale for anti-GITR cancer immunotherapy.
Knee DA; Hewes B; Brogdon JL
Eur J Cancer; 2016 Nov; 67():1-10. PubMed ID: 27591414
[TBL] [Abstract][Full Text] [Related]
14. Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.
Deppisch N; Ruf P; Eißler N; Lindhofer H; Mocikat R
Oncotarget; 2017 Jan; 8(3):4520-4529. PubMed ID: 27966460
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies in cancer immunotherapy.
Chen S; Li J; Li Q; Wang Z
Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163
[TBL] [Abstract][Full Text] [Related]
16. Pre-immunization of donor lymphocytes with GITR agonistic antibody enhances antitumor immunity in autologous hematopoietic stem cell transplantation.
Henmi M; Shibasaki C; Mizoguchi Y; Hirata A; Sawai E; Narumi K; Aoki K
Biochem Biophys Res Commun; 2019 Jan; 509(1):96-101. PubMed ID: 30579597
[TBL] [Abstract][Full Text] [Related]
17. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Selby MJ; Engelhardt JJ; Quigley M; Henning KA; Chen T; Srinivasan M; Korman AJ
Cancer Immunol Res; 2013 Jul; 1(1):32-42. PubMed ID: 24777248
[TBL] [Abstract][Full Text] [Related]
18. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
Chen W; Pandey M; Sun H; Rolong A; Cao M; Liu D; Wang J; Zeng L; Hunter A; Lin S
MAbs; 2021; 13(1):1914359. PubMed ID: 33870864
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Miyazaki M; Ikeda S; Tsumura H
Oncol Rep; 2015 Oct; 34(4):1995-2001. PubMed ID: 26239052
[TBL] [Abstract][Full Text] [Related]
20. Modulation of CTLA-4 and GITR for cancer immunotherapy.
Avogadri F; Yuan J; Yang A; Schaer D; Wolchok JD
Curr Top Microbiol Immunol; 2011; 344():211-44. PubMed ID: 20563707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]